Patritumab Deruxtecan

Phase 3

Daiichi Sankyo (DSKYF)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Sep '27

DSKYFPhase 2$34.8B

Patritumab deruxtecan Phase 2 Est. Readout

Patritumab Deruxtecan• Nonsquamous Non-small Cell Lung Cancer152

Sep 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Nonsquamous Non-small Cell Lung Cancer

View Full Landscape

Drug Information

Target Indication

Nonsquamous Non-small Cell Lung Cancer

Clinical Trial

NCT05338970

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

DSKYF

Daiichi Sankyo

Healthcare•North America•NASDAQ

Related Pipeline

T-DXdPhase 3

Advanced Cancer

QuizartinibPhase 3

Leukemia

DalteparinPhase 3

Venous Thromboembolism (VTE)

cevimeline hydrochloridePhase 3

Head and Neck Cancer

DS-8201aPhase 3

Neoplasm, Gastrointestinal

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts